SEARCH

SEARCH BY CITATION

References

  • 1
    Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002; 51: 5626.
  • 2
    Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121: 9007.
  • 3
    Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001; 96: 155862.
    Direct Link:
  • 4
    Aadland E, Schrumpf E, Fausa O, et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987; 22: 65564.
  • 5
    Quigley EM, LaRusso NF, Ludwig J, MacSween RN, Birnie GG, Watkinson G. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1983; 85: 11605.
  • 6
    Whiteside TL, Lasky S, Si L, Van Thiel DH. Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis. Hepatology 1985; 5: 46874.
  • 7
    Snook JA, Chapman RW, Sachdev GK, et al. Peripheral blood and portal tract lymphocyte populations in primary sclerosing cholangitis. J Hepatol 1989; 9: 3641.
  • 8
    Hashimoto E, Lindor KD, Homburger HA, et al. Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc 1993; 68: 104955.
  • 9
    Klein RLM, Leuschner U, Berg PA. TH1- and TH2-cytokine profiles in autoimmune liver disorders. J Hepatol 1997; 26: 112 (Abstract).
  • 10
    Mitchell SA, Chapman RW, Fleming KA. Enhanced cytokine mRNA expression in primary sclerosing cholangitis and autoimmune liver disease. Gastroenterology 1997; 112: A757 (abstract).
  • 11
    Chapman RW, Kelly PM, Heryet A, Jewell DP, Fleming KA. Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis. Gut 1988; 29: 4227.
  • 12
    Broome U, Glaumann H, Hultcrantz R, Forsum U. Distribution of HLA-DR, HLA-DP, HLA-DQ antigens in liver tissue from patients with primary sclerosing cholangitis. Scand J Gastroenterol 1990; 25: 548.
  • 13
    Angulo P, Peter JB, Gershwin ME, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000; 32: 1827.
  • 14
    Farrant JM, Doherty DG, Donaldson PT, et al. Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 1992; 16: 3905.
  • 15
    Spurkland A, Saarinen S, Boberg KM, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999; 53: 45969.
  • 16
    Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 31959.
    Direct Link:
  • 17
    Satsangi J, Chapman RW, Haldar N, et al. A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 2001; 121: 12430.
  • 18
    Donaldson PT, Farrant JM, Wilkinson ML, Hayllar K, Portmann BC, Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991; 13: 12933.
  • 19
    Donaldson PT, Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 2002; 35: 55564.
  • 20
    Donaldson PT, Norris S, Constantini PK, Bernal W, Harrison P, Williams R. The interleukin-1 and interleukin-10 gene polymorphisms in primary sclerosing cholangitis: no associations with disease susceptibility/resistance. J Hepatol 2000; 32: 8826.
  • 21
    Eng FJ, Friedman SL. Fibrogenesis. I: New insights into hepatic stellate cell activation: the simple becomes complex. Am J Physiol Gastrointest Liver Physiol 2000; 279: G7G11.
  • 22
    Saarinen S, Broome U, Ligers A, et al. CTLA-4 gene polymorphism associated with primary sclerosing cholangitis (PSC). J Hepatol 1998; 28: 124 (abstract P/CO7/002).
  • 23
    Agarwal K, Hudson M, Harrison P, et al. No association between primary sclerosing cholangitis (PSC) and CTLA-4 gene polymorphism. Hepatology 2000; 32: 173A (abstract No. 44).
  • 24
    Vierling J. Aetiopathogenesis of primary sclerosing cholangitis. In: Manns, PCR, Stieihl, A, Wiesner, R, eds. Primary Sclerosing Cholangitis. London, UK: Kluwer Academic Publishers, 1998.
  • 25
    Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002; 359: 1507.
  • 26
    Grant AJ, Lalor PF, Hubscher SG, Briskin M, Adams DH. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 2001; 33: 106572.
  • 27
    Hillan KJ, Hagler KE, MacSween RN, et al. Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease. Liver 1999; 19: 50918.
  • 28
    Spirli C, Fabris L, Duner E, et al. Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 2003; 124: 73753.
  • 29
    Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000; 60: 18490.
  • 30
    Shepherd HA, Selby WS, Chapman RW, et al. Ulcerative colitis and persistent liver dysfunction. Q J Med 1983; 52: 50313.
  • 31
    Schrumpf E, Elgjo K, Fausa O, Gjone E, Kolmannskog F, Ritland S. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980; 15: 68997.
  • 32
    Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 131923.
  • 33
    Chapman RW, Cottone M, Selby WS, Shepherd HA, Sherlock S, Jewell DP. Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis. Gut 1986; 27: 8691.
  • 34
    Duerr RH, Targan SR, Landers CJ, et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100: 138591.
  • 35
    Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17: 4117.
  • 36
    Vitellas KM, El-Dieb A, Vaswani KK, et al. MR cholangiopancreatography in patients with primary sclerosing cholangitis: interobserver variability and comparison with endoscopic retrograde cholangiopancreatography. AJR Am J Roentgenol 2002; 179: 399407.
  • 37
    Vitellas KM, Enns RA, Keogan MT, et al. Comparison of MR cholangiopancreatographic techniques with contrast-enhanced cholangiography in the evaluation of sclerosing cholangitis. AJR Am J Roentgenol 2002; 178: 32734.
  • 38
    Fleming KA, Boberg KM, Glaumann H, Bergquist A, Smith D, Clausen OP. Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2001; 34: 3605.
  • 39
    Ludwig J, La Russo NF, Wiesner RHP. Primary sclerosing cholangitis. In: Peters, RLCJ, ed. Contemporary Issues in Surgical Pathology. New York, USA: Churchill Livingstone, 1986: 193213.
  • 40
    Broome U, Glaumann H, Lindstom E, et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002; 36: 5869.
  • 41
    Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002; 35: 1494500.
  • 42
    Bjornsson E, Boberg KM, Cullen S, Fleming K, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002; 51: 7315.
  • 43
    Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 88490.
  • 44
    Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997; 27: 10228.
  • 45
    Mazzella G, Rizzo N, Azzaroli F, et al. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers. Hepatology 2001; 33: 5048.
  • 46
    Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of ursodeoxycholic acid in cystic fibrosis. Hepatology 1996; 23: 148490.
  • 47
    Jacquemin E, Hermans D, Myara A, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997; 25: 51923.
  • 48
    Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 97581.
  • 49
    Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol 2001; 35: 13446.
  • 50
    Guicciardi ME, Gores GJ. Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways. Hepatology 2002; 35: 9713.
  • 51
    Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36: 52531.
  • 52
    Van Nieuwkerk CM, Elferink RP, Groen AK, et al. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 1996; 111: 16571.
  • 53
    Beuers U, Bilzer M, Chittattu A, et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 2001; 33: 120616.
  • 54
    Fickert P, Zollner G, Fuchsbichler A, et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 2001; 121: 17083.
  • 55
    Kurz AK, Graf D, Schmitt M, Vom Dahl S, Haussinger D. Tauroursodeoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats. Gastroenterology 2001; 121: 40719.
  • 56
    Qiao L, Yacoub A, Studer E, et al. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology 2002; 35: 77989.
  • 57
    Bergamini A, Dini L, Baiocchi L, et al. Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells. Hepatology 1997; 25: 92733.
  • 58
    Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16: 70714.
  • 59
    Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994; 20: 5764.
  • 60
    Okolicsanyi L, Groppo M, Floreani A, et al. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig Liver Dis 2003; 35: 32531.
  • 61
    Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004; 40: 6938.
  • 62
    Olsson RG, Boberg KM, Schaffalitzky de Muckadel O, et al. Five year treatment with high dose UDCA in PSC (abstract). J Hepatol 2004; 40: 161 (abstract 551).
  • 63
    Sivak MV Jr, Farmer RG, Lalli AF. Sclerosing cholangitis: its increasing frequency of recognition and association with inflammatory bowel disease. J Clin Gastroenterol 1981; 3: 2616.
  • 64
    Burgert SL, Brown BP, Kirkpatrick RB. Positive corticosteroid response in early primary sclerosing cholangitis (abstract). Gastroenterology 1984; 86: 1037(A).
  • 65
    Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991; 86: 5761.
  • 66
    Boberg KM, Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003; 38: 9915.
  • 67
    Parkes M, Booth JC, Pillai G, Mee AS. Do steroids help jaundice caused by primary sclerosing cholangitis? J Clin Gastroenterol 2001; 33: 31922.
  • 68
    Tjandra K, Le T, Swain MG. Glucocorticoid receptors are downregulated in hepatic T lymphocytes in rats with experimental cholangitis. Gut 2003; 52: 136370.
  • 69
    Angulo P, Batts KP, Jorgensen A. Budesonide in the treatment of primary sclerosing cholangitis: a pilot study (abstract). Hepatology 1999; 30: 477A.
  • 70
    van Hoogstraten HJ, Vleggaar FP, Boland GJ, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 2000; 95: 201522.
    Direct Link:
  • 71
    Grijm R, Huibregtse K, Bartelsman J, Mathus-Vliegen EM, Dekker W, Tytgat GN. Therapeutic investigations in primary sclerosing cholangitis. Dig Dis Sci 1986; 31: 7928.
  • 72
    Jeffrey GP, Reed WD, Laurence BH, Shilkin KB. Primary sclerosing cholangitis: clinical and immunopathological review of 21 cases. J Gastroenterol Hepatol 1990; 5: 13540.
  • 73
    Craig PI, Willaims SJ, Hatfield ARW, Ng M, Cotton PB. Endoscopic management of primary sclerosing cholangitis (abstract). Gut 1990; 31: 1182A.
  • 74
    Allison MC, Burroughs AK, Noone P, Summerfield JA. Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study. J Hepatol 1986; 3: 11822.
  • 75
    Knox TA, Kaplan MM. Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol 1991; 86: 54652.
  • 76
    Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994; 106: 4949.
  • 77
    Lindor KD, Jorgensen RA, Anderson ML, Gores GJ, Hofmann AF, LaRusso NF. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 1996; 91: 5115.
  • 78
    Wagner A. Azathioprine treatment in primary sclerosing cholangitis. Lancet 1971; 2: 6634.
  • 79
    Javett SL. Azathioprine in primary sclerosing cholangitis. Lancet 1971; 1: 810.
  • 80
    Kyokane K, Ichihara T, Horisawa M, et al. Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid. Hepatogastroenterology 1994; 41: 44952.
  • 81
    Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 4559.
  • 82
    Duchini A, Younossi ZM, Saven A, Bordin GM, Knowles HJ, Pockros PJ. An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol 2000; 31: 2926.
  • 83
    Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 233842.
    Direct Link:
  • 84
    Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004; 49: 14.
  • 85
    Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, Zum Buschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999; 131: 9436.
  • 86
    LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988; 95: 103642.
  • 87
    Olsson R, Broome U, Danielsson A, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995; 108: 1199203.
  • 88
    Boyko EJ, Koepsell TD, Perera DR, Inui TS. Risk of ulcerative colitis among former and current cigarette smokers. N Engl J Med 1987; 316: 70710.
  • 89
    Tobin MV, Logan RF, Langman MJ, McConnell RB, Gilmore IT. Cigarette smoking and inflammatory bowel disease. Gastroenterology 1987; 93: 31621.
  • 90
    Mitchell SATM, Orchard TR, Jewell DP, Fleming KA, Chapman RW. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut 2002; 51: 16.
  • 91
    Angulo P, Bharucha AE, Jorgensen RA, et al. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci 1999; 44: 6027.
  • 92
    Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, Hop WC, van Erpecum KJ. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur J Gastroenterol Hepatol 2001; 13: 1715.
  • 93
    Myburgh JA. Surgical biliary drainage in primary sclerosing cholangitis. The role of the Hepp-Couinaud approach. Arch Surg 1994; 129: 105762.
  • 94
    Ponsioen CY, Lam K, van Milligen de Wit AW, Huibregtse K, Tytgat GN. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol 1999; 94: 24037.
    Direct Link:
  • 95
    van Milligen de Wit AW, van Bracht J, Rauws EA, Jones EA, Tytgat GN, Huibregtse K. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1996; 44: 2939.
  • 96
    Stiehl A, Rudolph G, Kloters-Plachky P, Sauer P, Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36: 1516.
  • 97
    Stiehl A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997; 26: 5606.
  • 98
    Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002; 37: 120511.
  • 99
    Brandsaeter B, Isoniemi H, Broome U, et al. Liver transplantation for primary sclerosing cholangitis: predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40: 81522.
  • 100
    Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998; 27: 3116.
  • 101
    Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000; 31: 711.
  • 102
    Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 (Suppl. 6): VI19.
  • 103
    Kuszyk BS, Soyer P, Bluemke DA, Fishman EK. Intrahepatic cholangiocarcinoma: the role of imaging in detection and staging. Crit Rev Diagn Imaging 1997; 38: 5988.
  • 104
    Vazquez-Sequeiros E, Baron TH, Clain JE, et al. Evaluation of indeterminate bile duct strictures by intraductal US. Gastrointest Endosc 2002; 56: 3729.
  • 105
    Levy MJ, Vazquez-Sequeiros E, Wiersema MJ. Evaluation of the pancreaticobiliary ductal systems by intraductal US. Gastrointest Endosc 2002; 55: 397408.
  • 106
    Tamada K, Nagai H, Yasuda Y, et al. Transpapillary intraductal US prior to biliary drainage in the assessment of longitudinal spread of extrahepatic bile duct carcinoma. Gastrointest Endosc 2001; 53: 3007.
  • 107
    Kluge R, Schmidt F, Caca K, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001; 33: 102935.
  • 108
    Kato T, Tsukamoto E, Kuge Y, et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging 2002; 29: 104754.
  • 109
    Keiding S, Hansen SB, Rasmussen HH, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998; 28: 7006.
  • 110
    Ferrari AP Jr, Lichtenstein DR, Slivka A, Chang C, Carr-Locke DL. Brush cytology during ERCP for the diagnosis of biliary and pancreatic malignancies. Gastrointest Endosc 1994; 40: 1405.
  • 111
    Boberg KM, Jebsen P, Clausen OP, Aabakken L, Brekke I, Schrumpf E. Cholangiocarcinoma in situ in primary sclerosing cholangitis: diagnosis by brush cytology and treatment by liver transplantation. J Hepatol 2003; 39: 453.
  • 112
    Lee JG, Leung JW, Baillie J, Layfield LJ, Cotton PB. Benign, dysplastic, or malignant-making sense of endoscopic bile duct brush cytology: results in 149 consecutive patients. Am J Gastroenterol 1995; 90: 7226.
  • 113
    Reeves ME, DeMatteo RP. Genes and viruses in hepatobiliary neoplasia. Semin Surg Oncol 2000; 19: 8493.
  • 114
    Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002; 123: 10908.
  • 115
    Boberg KM, Schrumpf E, Bergquist A, et al. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol 2000; 32: 37480.
  • 116
    Sturm PD, Rauws EA, Hruban RH, et al. Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis. Clin Cancer Res 1999; 5: 62935.
  • 117
    de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999; 341: 136878.
  • 118
    Morales CP, Burdick JS, Saboorian MH, Wright WE, Shay JW. In situ hybridization for telomerase RNA in routine cytologic brushings for the diagnosis of pancreaticobiliary malignancies. Gastrointest Endosc 1998; 48: 4025.
  • 119
    Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 1995; 108: 8659.
  • 120
    Hultcrantz R, Olsson R, Danielsson A, et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999; 30: 66973.
  • 121
    Lindberg B, Arnelo U, Bergquist A, et al. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 2002; 34: 90916.
  • 122
    Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004; 39: 20410.
  • 123
    Farges O, Malassagne B, Sebagh M, Bismuth H. Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 1995; 117: 14655.
  • 124
    Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cholangitis. Liver 2000; 20: 97103.
  • 125
    Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999; 29: 10506.
  • 126
    Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991; 100: 17107.
  • 127
    Dickson ER, Murtaugh PA, Wiesner RH, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992; 103: 1893901.
  • 128
    Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 6105.
  • 129
    Boberg KM, Rocca G, Egeland T, et al. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 2002; 35: 6527.
  • 130
    Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997; 225: 47281; discussion 481–3.
  • 131
    Iwatsuki S, Todo S, Marsh JW, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998; 187: 35864.
  • 132
    De Vreede I, Steers JL, Burch PA, et al. Prolonged disease free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transplant 2000; 6: 30916.
  • 133
    Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002; 2: 7749.
  • 134
    Ricci P, Therneau TM, Malinchoc M, et al. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. Hepatology 1997; 25: 6727.
  • 135
    Neuberger J, Gunson B, Komolmit P, Davies MH, Christensen E. Pretransplant prediction of prognosis after liver transplantation in primary sclerosing cholangitis using a Cox regression model. Hepatology 1999; 29: 13759.
  • 136
    Narumi S, Roberts JP, Emond JC, Lake J, Ascher NL. Liver transplantation for sclerosing cholangitis. Hepatology 1995; 22: 4517.
  • 137
    Vera A, Moledina S, Gunson B, et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002; 360: 19434.
  • 138
    Khettry U, Keaveny A, Goldar-Najafi A, et al. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum Pathol 2003; 34: 112736.
  • 139
    Kugelmas M, Spiegelman P, Osgood MJ, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003; 9: 72732.
  • 140
    Sheng R, Campbell WL, Zajko AB, Baron RL. Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease. AJR Am J Roentgenol 1996; 166: 110913.
  • 141
    Harrison RF, Davies MH, Neuberger JM, Hubscher SG. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis? Hepatology 1994; 20: 35661.
  • 142
    Jeyarajah DR, Netto GJ, Lee SP, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation 1998; 66: 13006.
  • 143
    Kubota T, Thomson A, Clouston AD, et al. Clinicopathologic findings of recurrent primary sclerosing cholangitis after orthotopic liver transplantation. J Hepatobiliary Pancreat Surg 1999; 6: 37781.
  • 144
    Liden H, Norrby J, Friman S, Olausson M. Liver transplantation for primary sclerosing cholangitis – a single-center experience. Transpl Int 2000; 13 (Suppl. 1): S1624.
  • 145
    Yusoff IF, House AK, De Boer WB, et al. Disease recurrence after liver transplantation in Western Australia. J Gastroenterol Hepatol 2002; 17: 2037.
  • 146
    MacLean AR, Lilly L, Cohen Z, O'Connor B, McLeod RS. Outcome of patients undergoing liver transplantation for primary sclerosing cholangitis. Dis Colon Rectum 2003; 46: 11248.
  • 147
    Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002; 8: 57581.
  • 148
    Rai RM, Boitnott J, Klein AS, Thuluvath PJ. Features of recurrent primary sclerosing cholangitis in two consecutive liver allografts after liver transplantation. J Clin Gastroenterol 2001; 32: 1514.
  • 149
    Bjoro K, Schrumpf E. Liver transplantation for primary sclerosing cholangitis. J Hepatol 2004; 40: 5707.
  • 150
    Gopal DV, Corless CL, Rabkin JM, Olyaei AJ, Rosen HR. Graft failure from severe recurrent primary sclerosing cholangitis following orthotopic liver transplantation. J Clin Gastroenterol 2003; 37: 3447.
  • 151
    Solano E, Khakhar A, Bloch M, et al. Liver transplantation for primary sclerosing cholangitis. Transplant Proc 2003; 35: 24314.
  • 152
    Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997; 40: 4516.
  • 153
    Rabinovitz M, Gavaler JS, Schade RR, Dindzans VJ, Chien MC, Van Thiel DH. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 1990; 11: 711.
  • 154
    Perdigoto R, Weisner R, LaRusso NRD. Inflammatory bowel disease associated with primary sclerosing cholangitis: incidence, severity and relationship to liver disease. Gastroenterology 1991; 100: A238 (abstract).
  • 155
    Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 14048.
  • 156
    Harewood GC, Loftus EV, Tremaine WJ, et al. TWe. ‘PSC-IBD’: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gastroenterology 1999; 116: G3178.
  • 157
    Loftus EV Jr, Sandborn WJ, Tremaine WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology 1996; 110: 43240.
  • 158
    Broome U, Lindberg G, Lofberg R. Primary sclerosing cholangitis in ulcerative colitis – a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992; 102: 187780.
  • 159
    Choi PM, Nugent FW, Rossi RL. Relationship between colorectal neoplasia and primary sclerosing cholangitis in ulcerative colitis. Gastroenterology 1992; 103: 17079.
  • 160
    D'Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993; 88: 11748.
  • 161
    Gurbuz AK, Giardiello FM, Bayless TM. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Dis Colon Rectum 1995; 38: 3741.
  • 162
    Brentnall TA, Haggitt RC, Rabinovitch PS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996; 110: 3318.
  • 163
    Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996; 91: 448.
  • 164
    Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999; 94: 16439.
    Direct Link:
  • 165
    Leidenius MH, Farkkila MA, Karkkainen P, Taskinen EI, Kellokumpu IH, Hockerstedt KA. Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis. Scand J Gastroenterol 1997; 32: 70611.
  • 166
    Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997; 41: 5225.
  • 167
    Marchesa P, Lashner BA, Lavery IC, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997; 92: 12858.
  • 168
    Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study. Cancer 1998; 82: 8226.
  • 169
    Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001; 44: 7785.
  • 170
    Cairns S, Scholefield JH. Guidelines for colorectal cancer screening in high risk groups. Gut 2002; 51 (Suppl. 5): V12.
  • 171
    Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 88993.
  • 172
    Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 8995.
  • 173
    Hill MJ, Melville DM, Lennard-Jones JE, Neale K, Ritchie JK. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 1987; 2: 1856.
  • 174
    Bayerdorffer E, Mannes GA, Richter WO, et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993; 104: 14551.
  • 175
    Stadler J, Yeung KS, Furrer R, Marcon N, Himal HS, Bruce WR. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer. Cancer Lett 1988; 38: 31520.
  • 176
    Reddy BS, Wynder EL. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer 1977; 39: 25339.
  • 177
    Ochsenkuhn T, Bayerdorffer E, Meining A, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999; 85: 16649.
  • 178
    Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998; 4: 16578.
  • 179
    Martinez JD, Stratagoules ED, LaRue JM, et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998; 31: 1118.
  • 180
    Wolf JM, Rybicki L, Ba L. Ursodeoxycholic acid is not chemoprotective for colorectal cancer in ulcerative colitis patients with primary sclerosing cholangitis. Gastroenterology 2001; 121: 2276(A).
  • 181
    Stahlberg D, Veress B, Tribukait B, Broome U. Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 2003; 46: 7708.
  • 182
    O‘Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991; 14: 83847.
  • 183
    Lo SK, Hermann R, Chapman RW, et al. Ursodeoxycholic acid in primary sclerosing cholangitis: a double blind placebo controlled trial (abstract). Hepatology 1992; 16: 92A.
  • 184
    De Maria N, Colantoni A, Rosenbloom E, Van Thiel DH. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology 1996; 43: 14729.
  • 185
    Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 6915.
  • 186
    van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single vs. multiple daily doses. J Hepatol 1998; 29: 41723.
  • 187
    Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 2004; 99: 53842.
    Direct Link:
  • 188
    Liden H, Norrby J, Gabel M, Friman S, Olausson M. Outcome after liver transplantation for primary sclerosing cholangitis. Transplant Proc 2001; 33: 24523.
  • 189
    Saldeen K, Friman S, Olausson M, Olsson R. Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastroenterol 1999; 34: 53540.